JC20 Rec'd PCT/PTO Q 6 MAY 2005

Please type a plus sign (+) inside this box	+
Please type a plus sign (+) inside this box	

Sheet

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO Intesigned **Application Number** INFORMATION DISCLOSURE May 6, 2005 Filing Date STATEMENT BY APPLICANT Eric ROUGEMOND et al. First Named Inventor Unassigend **Group Art Unit** Unassigned Examiner Name (use as many sheets as necessary) MERCK-2999 Attorney Docket Number of

N. SPINIS		NON PATENT UTERATURE DOCUMENTS	11 2 3
Examiner Initials		include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, local average average), catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т3
D	1	ZANNAD F ET AL: "FOSIDIAL: A randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics" FUNDAMENTAL & CLINICAL PHARMACOLOGY, ELSEVIER, PARIS, FR. Vol. 16, no. 5, 2002, pages 353-360, XP002247194	
	2	SICA D A ET AL: "Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease" DRUG SAFETY 2000 NEW ZEALAND, vol. 22, no. 5, 2000, pages 350-360, XP009024422.	
A	3	STAFFELD C G ET AL: "Cardiac disease in patients with end-stage renal disease" CARDIOLOGY CLINICS 1995 UNITED STATES, vol. 13, no. 2, 1995, pages 209-223, XP009024432.	
		•	
		·	
		,	
			
			
			
			
			
			
		·	├──
	1	·	

Examiner	1/1/1	148	Date Considered	4/14/04
Signature		10		see Onew time through citation if not in conformant

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, braw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.